Press review

 - 

Italian pharma calls on new government to ensure regulation keeps pace with innovation in treatments

Country : Italy

Keywords :
MILAN, 6 Sep (APM) - The Italian pharma industry has called on the new government to ensure regulation keeps pace with innovation so patients can have access to the latest treatments, Il Sole 24 Ore reports on Friday.
The administration was sworn in on Thursday (APMHE 64249). Farmindustria wished it well shortly afterwards in a statement, the paper said.
The industry body highlighted how the new health minister, Roberto Speranza, has come to office at a time when life sciences are undergoing a profound and rapid transformation, including extensive innovation in treatments and the development of increasingly personalised therapies.
Farmindustria described it as a revolution which will require policies to ensure progress in pharmaceutical research is made quickly available to patients. "It is important that we have effective pharmaceutical governance with rules and procedures that can keep pace with innovation," the industry body said.
It noted that Italy has becoming the leading producer of drugs in the EU. It said the industry is willing to continue to contribute by providing skilled jobs, investments and economic and social growth.
Farmindustria thanked the outgoing health minister Giulia Grillo for having started a dialogue and suggested that it is in the interests of patients that this should continue with the new government.

New health minister's party highlights generics, innovation as priorities

The new health minister's party, the centre-left Liberi e Uguali (LeU), sees increasing generics use and access to innovative drugs as two of its priorities in pharma, according to Friday’s Il Sole 24 Ore.
The paper published a health programme put out by LeU at the end of 2017 to illustrate Roberto Speranza's possible approach to healthcare policy.
In the section on drugs, his party highlighted how generics accounted for just 19% of drugs used in 2015 in Italy compared to a 52% EU average. It suggested special campaigns are needed to boost use.
LeU also called for a new strategy for drugs which are shown to be innovative to allow access for patients at "reasonable costs". It suggested that the way medicines agency AIFA operates needs to be changed.
Drugs spending and budgets also need to be reviewed while independent research should be promoted better. According to the party, a publicly-funded company for the production and sale of drugs should also be started.

Far-right leader slams new health minister for lack of experience

The leader of the far-right League, Matteo Salvini, has reacted angrily to the formation of a new government, especially the new health minister, Quotidiano Sanità reported on Thursday.
"Wrong people in the wrong place and with no experience," he wrote on his Facebook page. "Let's start with basic healthcare, the right to health services, the right to life, to treatment, hospitals, nurses, doctors. And who (did they choose) as the health minister? Speranza of LeU who has zero ability in healthcare, zero experience in public or private health."
Other comments about the health minister published by Quotidiano Sanità ranged from neutral to positive but none, apart from Salvini's, were negative.

Resolvin may be key to slowing Parkinson's disease progression

Progression of Parkinson's disease could be slowed by resolvin, a molecule produced by our own bodies, Il Sole 24 Ore reported on Monday.
Scientists have been looking at the relationship between inflammatory states and degenerative diseases for some time, the paper said.
Italian researchers from Rome's Tor Vergata University and other Italian research centres observed a reduced level of resolvin D1 in patients with Parkinson's. They used laboratory models to test the effectiveness of administering resolvin D1.
After two months of treatment there was a progressive reduction in inflammation and a slowing of the neurodegenerative process which leads to the destruction of neutrons which produce dopamine.
Their study was published in Nature Communications on Monday, the paper said. The scientists concluded that the research shows the potential for identifying effective therapies as well as providing markers for early diagnosis of Parkinson’s disease.

Sanofi makes senior appointments in Italy

Sanofi has made senior appointments in Italy, About Pharma reported on Tuesday.
Marcello Cattani took over as general manager of Sanofi Genzyme at the beginning of September. Mauro Ninci became the new medical affairs head and will also assume the role of country medical chair for all of Sanofi, the specialist publication said.
Both executives will join Sanofi's executive committee in Italy and Cattani will also be part of Sanofi Genzyme's executive committee for Europe.
Cattani started his career at Bristol-Myers Squibb and also worked for Procter & Gamble Pharma. He joined Sanofi in 2015 as strategic branding & value director, became head of the onco-haematology franchise and head of marketing excellence in Sanofi Genzyme.
Ninci has previously worked for Recordati and Verigen, a biotech bought by Genzyme in 2015.
rg/nh

[RG6PXEIJQ]

TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT

Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.